
The identification and remediation of underperformance are essential responsibilities of postgraduate medical training programs. Despite calls for a programmatic approach, remediation practices remain inconsistent, with many institutions lacking formal policies. The aim of this study was to identify the core components for developing remediation frameworks for postgraduate trainees. A narrative review format was chosen. Eligible papers for inclusion included studies, opinion pieces, systematic reviews, and meta-analyses. Fifty-four papers were included for analysis. We identified seventeen components which were organized into three overarching phases: (1) assess and support, (2) plan and implement, and (3) evaluate and follow-up. ‘Assess and support’ components included: ensure an accurate diagnosis; give feedback; ensure the trainee’s perspective is heard; address external stressors and system causes; provide emotional support; address attitudes and motivation of the trainee; and destigmatize remediation. ‘Plan and implement’ components included: involve remediation and educational experts; create individualized remediation plans; document plans clearly; and teach goal setting and self-regulation. ‘Evaluate and follow-up’ components included: monitor progress and reassess; feed forward carefully; separate those conducting from those judging remediation; ensure transparent policies and due process; and develop compassionate exit pathways. Guiding principles such as transparency, fairness, and alignment with educational theory often supported these components. This narrative review has identified the components to be considered when developing remediation frameworks in postgraduate medical education. Understanding core components and their connections helps design literature-informed frameworks that can be tailored to local contexts, optimizing remediation outcomes in postgraduate training programs.
Cigarette smoking is a major driver of airway and systemic inflammation and contributes to the development and progression of chronic obstructive pulmonary disease (COPD). This study compared peripheral blood inflammatory markers and immune cell profiles in smokers with and without COPD and in non-smoking controls. In this cross-sectional study, blood samples were collected from 80 participants (n = 20/group): non-smoker controls (NS), smokers with normal lung function (NLFS), current smokers with COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). Total white cell count (WCC) and leukocyte differentials (neutrophils, lymphocytes, monocytes, eosinophils) were measured using an automated haematology analyser (Sysmex XN2000). Systemic inflammatory markers were measured using C-reactive protein (CRP, Roche Cobas Pro) and erythrocyte sedimentation rate (ESR, Diesse VES-MATIC Easy). Lung function parameters (including FEV1, FVC, DLco, FEF25–75
Autism spectrum disorder (autism) describes a heterogeneous neurodevelopmental phenotype arising from the interplay of environmental and genetic factors in early life. In a general population birth cohort, we employed a scoping approach to identify prospective associations between prenatal and birth factors and a subsequent autism diagnosis. Factors associated with increased likelihood of autism included those related to i) maternal health (maternal pre-pregnancy body mass index, pre-existing maternal mental health conditions, maternal use of selective serotonin reuptake inhibitors) ii) environmental exposures (maternal passive tobacco smoke exposure, and exposure to vinyl floors) iii) demographic factors (socioeconomic disadvantage). Factors associated with a decreased likelihood of autism included maternal dietary nutrition and supplementation (higher folic acid, magnesium, and iron, as well as adherence to the Australian Dietary Guidelines). Our findings extend the evidence that autism may have a multifactorial origin in early life. Further studies should explore the composite effects of these prenatal and birth factors on autism outcomes via shared biological pathways, such as inflammation, and oxidative stress, in concert with genetic predisposition.
BACKGROUND:Approximately 10% of hospitalized patients globally report a penicillin allergy, leading to inappropriate antibiotic prescribing and inferior healthcare outcomes. Evidence supporting the effectiveness and widespread implementation of inpatient penicillin direct oral challenge (DOC) is limited. METHODS:A prospective, multicenter, international type 2 hybrid effectiveness-implementation study was conducted in 40 hospitals across 8 countries between November 2022 and May 2025. Adult inpatients with a penicillin allergy underwent assessment using a digital penicillin allergy toolkit (National Antibiotic Allergy Network [NAAN] App). According to site clinical practice, participants received penicillin DOC (effectiveness intervention) or assessment only. Participating sites received bimonthly audit and feedback at least 3 months after site activation (implementation strategy). Observational data were used to emulate a target trial to examine secondary effectiveness outcomes, including antibiotic prescribing at 90 days in DOC versus non-DOC participants. The primary implementation outcome was adoption of the NAAN App within 6 months of site activation. RESULTS:Among 5121 participants assessed, 1573 (30.7%) underwent DOC, of which 1502 (95.5%) were delabeled. Of 71 (4.5%) participants with a positive DOC, 6 (0.4%) had a serious adverse event. Of 1852 inpatients in the target trial analysis, 892 underwent DOC and 960 underwent assessment only. Participants who underwent DOC were more likely to be prescribed penicillin (risk ratio [RR], 13.25 [95% confidence interval {CI}, 7.82-22.46]), and less likely to be prescribed World Health Organization (WHO) "Watch" or "Reserve" antibiotics (RR, 0.73 [95% CI, .60-.89]) at 90 days post evaluation. Within 6 months of site activation, 77 clinicians adopted the NAAN App. CONCLUSIONS:Multidisciplinary adoption of inpatient penicillin DOC was safe and significantly improved penicillin prescribing and reduced use of WHO restricted antibiotics.
BACKGROUND:Women with pre-eclampsia are at increased risk of later-life cardiovascular disease (CVD). Despite suggestions that women affected by pre-eclampsia should undergo routine CVD screening, uniform recommendations are lacking. Subclinical atherosclerosis provides a window of opportunity to identify and treat those at risk of CVD. Coronary artery calcium scoring (CAC), carotid intima-media thickness (CIMT) and ankle brachial index (ABI) are effective methods of detecting subclinical atherosclerosis. This systematic review sought to explore associations between timing of measurement and presence of subclinical atherosclerosis in women with a history of pre-eclampsia. METHODS:We searched the MEDLINE, EMBASE and CINAHL databases for all studies which reported subclinical atherosclerosis in women with a history of pre-eclampsia. Common and random effects models were used to examine the associations between pre-eclampsia and subclinical atherosclerosis. RESULTS:35 case-control studies comprising 20 235 women were included in the final analysis. 3376 had a history of pre-eclampsia. Among the 26 studies assessing CIMT, pre-eclampsia was associated with increased CIMT (standardised mean difference 0.63 (95% CI 0.32, 0.93)). This difference was present during pregnancy (0.65 (95% CI 0.33, 0.98)) and persisted for 12 months post partum (0.84 (95% CI 0.20, 1.47)) and beyond (0.50 (95% CI 0.01, 0.99)). Pooled analysis of the eight CAC studies also demonstrated that the odds of having subclinical atherosclerosis were 1.57 (95% CI 1.39, 1.77) times higher in women with a history of pre-eclampsia. CONCLUSIONS:Among women with a history of pre-eclampsia, subclinical atherosclerosis can be seen during pregnancy and persists long term. Our review supports the importance of early follow-up in patients who have had pre-eclampsia.